Evidence map›Paper›PMID 41561437›Full record

ArticleFrontiers in molecular neuroscience2025

Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD.

Sang Hwa Kim, Claire E Boos, Mark Scalf, Akasha K Wilkemeyer, Lloyd M Smith, Randal S Tibbetts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Sang Hwa Kim *Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Claire E Boos *Department of Chemistry, University of Wisconsin-Madison, Madison, WI, United States.
Mark ScalfDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, United States.
Akasha K WilkemeyerDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Lloyd M SmithDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, United States.
Randal S TibbettsDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.

Funding

Institutional Training in the Genomic SciencesT32HG002760 · NHGRI · UNIVERSITY OF WISCONSIN-MADISON · PI Qiongshi Lu · 2003 to 2026
$17.7M
Revealing Proteoforms: The Primary Effectors of Biological FunctionR35GM126914 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Lloyd M Smith · 2018 to 2026
$6.2M
Genetic analysis of UBQLN2-associated neurodegeneration in frontotemporal dementiaRF1AG069483 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI TIBBETTS, RANDAL SCOT · 2020 to 2020
$1.7M
Genome maintenance functions of CREB/ATF transcription factorsR01CA180765 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI TIBBETTS, RANDAL SCOT · 2013 to 2016
$1.1M
NCI NIH HHS R01 CA180765NHGRI NIH HHS T32 HG002760NIA NIH HHS RF1 AG069483NIGMS NIH HHS R35 GM126914
6 · The paper itself

Abstract

Ubiquilin-2 (UBQLN2) is a ubiquitin (Ub)-binding shuttle protein that is mutated in X-linked forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS/FTD-linked mutations in UBQLN2 disrupt its conformation, increasing its tendency to form cytoplasmic aggregates that may disrupt cellular regulation through loss-of-function (LOF) and gain-of-function (GOF) effects. Here, we performed quantitative mass spectrometry (MS)-based interactome analysis of wild-type (UBQLN2

Indexed as

ALSBAG6FTDPEG10UBQLN2

Identifiers

PMID41561437
PMCPMC12813162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.